Bismuth Triple vs Quadruple Therapy for H. pylori Infection
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 552 (estimated)
- Sponsor
- Kaohsiung Medical University · Other
This trial is looking for people with a Helicobacter pylori infection. Participants will compare two different treatment options for 14 days to see which works better and safely.
You may be able to join if
- I have been diagnosed with Helicobacter pylori infection
You may not be able to join if
- I am allergic to the study drug
- I have had gastric surgery
- I have severe liver cirrhosis
- I have uremia
- I have had cancer in the past five years
- I am pregnant or breastfeeding
- I am taking atazanavir sulfate
- I am taking rilpivirine hydrochloride
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Loading trial locations…